CURRICULUM VITAE

Name: Yong Li

Email: y.li@unsw.edu.au

Phone: +61-2-9113-2514

Fax: +61-2-9113-1393

Position: Principal Scientific Officer and Director of Cancer Research Laboratory, Cancer Care Centre, St George Hospital, Australia;
Associate Professor, Faculty of Medicine, UNSW Sydney, Australia
Institution: St George Hospital, University of New South Wales (UNSW) Sydney

Location: Level 2, Research and Education Centre, 4-10 South St, Kogarah, NSW 2217, Australia

Education: 1987-Bachelor of Medicine, Faculty of Medicine, Henan Medical University, People of Republic of China;
1992-MSc, Pediatrics, Faculty of Medicine, Henan Medical University, People of Republic of China;
2000-PhD, Immunology, Faculty of Medicine, University of New South Wales, Australia

Representative Careers: Associate Professor Li became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He have published more than 100 papers and book chapters in peer-reviewed journals including the high impact journals, "Blood", "Journal of Biological Chemistry", "Clinical Cancer Research", "Medicinal Research Reviews", "Cancer and Metastasis Reviews", "British Journal of Cancer" and "International Journal of Radiation Oncology, Biology, Physics". He is the senior/corresponding author in most of his publication. His Scopus career citations are 2559 since 1999. His Scopus h-index is 30 and Google i10 index is 70. Over the past 7 years, he has attracted 5.2 million AU$ from different funding sources including NHMRC, ARC, US Department Defence, Cancer Institute NSW, and Prostate Cancer Foundation of Australia and Prostate and Breast Cancer Foundation (PBCF) as the principal investigator. He has trained more than 12 PhD students in cancer research area.

Specialty & Present Interest: a): To investigate novel biomarkers from exosomes as liquid biuopsy for cancer diagnosis and developing personalized medicine; b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance and role of tumour microenvironment, cancer stem cells and epithelial-mesenchymal transition in cancer progression ; c): To use targeted cancer therapy and combination therapy to control metastatic and therapeutic resistant cancers.

Representative papers (up to 5):

1. **Li Y**, Li L, Waldey R, Reddel SW, Qi JC, Archis C, Collins A, Clark E, Colley M, Kouts S, Hassan NM, Mohammed A, Cunningham A, Wong GW, Stevens RL, Krilis SA. Identification of a population of mast

cells/basophils in human peripheral blood which is HIV-1 susceptible due to its surface expression of CD4 and the chemokine receptore CCR3, CCR5 and CXCR4. **Blood** 2001;97:3484-90.

2. **Li Y**, Song E, Rizvi SMA, Power CA, Beretov J, Raja C, Cozzi PJ, Bruchertseifer F, Apostolidis C, Allen BJ Russell PJ. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted a radioimmunoconjugates. **Clin Cancer Res** 2009;15:865-875 (corresponding author).

3. Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, **Li Y**. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. **Cancer Metast Rev** 2012;31:779-791.

4. Chang L, Graham P, Hao JL, Ni J, Bucci J, Cozzi P, Kearsley J, **Li Y**. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. **Cell Death Dis.** 2013;4:e875.

5. Ni J, Bucci J, Chang L, Malouf D, Graham P, **Li Y**. Targeting microRNAs in prostate cancer radiotherapy. **Theranostics** 2017; 7: 3243-3259.